Novartis
NEWS
The ASRS issued a note to its members about concerns regarding reports of vasculitis, an inflammation of the blood vessels and other complications that can lead to the loss of vision, as a potential side effect of treatment with Beovu.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
The spreading of the coronavirus that began in Wuhan, China has researchers and health officials worldwide studying the emerging virus and preparing to treat it and develop vaccines. With such an enormous global focus, it seems that new information about the virus and the infection is being published each day.
In its annual report, Novartis said it has stopped working on the years-long project and will record a $442 million impairment charge as a result.
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
JOBS
IN THE PRESS